论文部分内容阅读
目的:观察西妥昔单抗联合伊立替康治疗晚期结直肠癌的有效性与安全性。方法:全组共14例患者,均经病理组织学确诊,采用西妥昔单抗联合伊立替康单药或FOLFIRI方案治疗。结果:14例患者治疗后取得部分缓解3例,病情稳定7例,疾病进展4例,有效率21%,疾病控制率71%,中位生存期16周。主要的毒性反应是痤疮样皮疹和腹泻。结论:西妥昔单抗联合伊立替康为主方案对晚期结直肠癌患者有效。除痤疮样皮疹外,毒副作用无明显增加。
Objective: To observe the efficacy and safety of cetuximab combined with irinotecan in the treatment of advanced colorectal cancer. METHODS: A total of 14 patients in the entire group, all diagnosed by histopathology, were treated with cetuximab plus irinotecan alone or FOLFIRI. RESULTS: After treatment, 14 patients achieved partial remission in 3 cases, stable disease in 7 cases, disease progression in 4 cases, effective rate of 21%, disease control rate of 71%, and median survival period of 16 weeks. The main toxicities are acne-like rashes and diarrhea. Conclusion: Cetuximab combined with irinotecan-based regimen is effective for patients with advanced colorectal cancer. With the exception of acne-like skin rashes, there was no significant increase in side effects.